Exosomes – News and Features

Exosome Diagnostics to use the Applied Biosystems® (ABI) 7500 Fast Dx Real-Time PCR Instrument for the Company's exosome biofluid in-vitro diagnostics oncology program.

Partnership aims to advance clinical studies of Exosome biofluid molecular diagnostics technology in brain cancer.

File joint patent application for new peptides that support targeted diagnosis and therapies.

New RNA biofluid diagnostics for the detection, progression monitoring, and advanced disease risk stratification in prostate cancer.

Latest webinar aimed at those with a similar interest in the detection and speciation of exosomes and micro-vesicles.

Conference is designed to bring together researchers in the rapidly growing field of exosomes and microvesicles.

NanoSight reports the new publication in one of the most cited peer reviewed journals in nanoscience and nanotechnology, NanoMedicine.

In this paper researchers from the German Cancer Research Center demonstrate how the isolation of exosomes, being a minimally invasive procedure, opens new possibilities for diagnostics.

Exosome appoints Bob Carter MD, Carlos Cordon-Cardo MD, PhD, Keith Flaherty MD, John Quackenbush, PhD; to its Scientific Advisory Board.

A study published in Nature Communications by researchers at Massachusetts General Hospital/Harvard Medical School shows that tumor microvesicles contain retro-transposons, also known as "jumping genes" as well as amplified oncogene sequences. These discoveries expand further on the use of microvesicles such as exosomes as a powerful blood-based cancer diagnostic medium.